Infiltrating Bladder Urothelial Carcinoma
Conditions
Brief summary
This research trial studies quality of life after bladder-preservation chemotherapy and radiation therapy (chemo-radiotherapy) in patients with bladder cancer that has spread into or through the muscle layer of the bladder (muscle-invasive bladder cancer). Bladder-preservation chemo-radiotherapy is a standard treatment for patients with muscle-invasive bladder cancer, however, chemo-radiotherapy may cause urinary tract, bowel, and sexual late side effects that negatively affect patients' quality of life. Studying quality-of-life in patients with muscle-invasive bladder cancer after chemo-radiotherapy may help identify the long-term side effects of treatment and may help plan the best treatment in the future and improve patients' quality of life.
Detailed description
PRIMARY OBJECTIVES: I. To study health-related quality of life (HRQoL, or QOL) for patients undergoing protocol-based bladder-preservation chemo-radiation. OUTLINE: Patients complete the European Organization for Research and Treatment for Cancer (EORTC) QLQ-Bladder Cancer Muscle Invasive (BLM-C30) at baseline, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter after completion of chemo-radiotherapy.
Interventions
OTHERQuality-of-Life Assessment
Ancillary studies
OTHERQuestionnaire Administration
Ancillary studies
Sponsors
Jonsson Comprehensive Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed muscle-invasive urothelial cancer (no histology will be excluded) * No pelvic nodal metastases or distant metastases (based on computed tomography \[CT\], positron emission tomography \[PET\] or magnetic resonance imaging \[MRI\]) * Karnofsky performance status (KPS) \>= 70 * Ability to understand, and willingness to sign, the written informed consent * Patient will have either opted for bladder-sparing treatment as compared to radical cystectomy, or deemed medically inoperable * Following the recent recommendations from the International Consultation on Urological Diseases-European Association of Urology International Consultation on Bladder Cancer, eligible patients will be those with no hydronephrosis, no extensive carcinoma in situ (CIS), and no tumor invasion into the stroma of the prostate
Exclusion criteria
* Patients with any evidence of distant metastases * Prior pelvic radiotherapy * History of Crohn's disease or ulcerative colitis * Unable to receive chemotherapy * Histologies other than urothelial (eg. squamous cell carcinoma, adenocarcinoma, small cell)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Establish QOL with validated tools for patients undergoing bladder-preservation chemo-radiation | From the date of study entry up to 5 years | Validated Quality-of-Life questionnaires developed by the European Organization for Research and Treatment for Cancer (EORTC) will be used. The EORTC QLQ-BLM30 with 30 questions specific to muscle-invasive bladder cancer will be combined and used in conjunction with the general cancer questionnaire EORTC QLQ-C30 (Aaronson). |
Secondary
| Measure | Time frame |
|---|---|
| Quantify the rate of early and late grade 3 or higher GU or GI toxicity based on the CTCAE criteria | Up to 5 years |
| Overall survival | From the date of study entry to the date of death, assessed up to 5 years |
Countries
United States
Outcome results
None listed